The San Antonio Breast Cancer Symposium (SABCS) 2025 took place from December 9–12, 2025, in San Antonio, Texas, serving as one of the world’s premier forums for breast cancer research and clinical innovation. Bringing together oncologists, surgeons, radiologists, scientists, patient advocates, and industry leaders, SABCS 2025 showcased advances across the spectrum of breast oncology, from translational science and precision therapeutics to diagnostics, survivorship, and global care standards. The meeting featured high-impact scientific presentations, educational sessions, late-breaking data, and extensive industry participation. Core content was also made available online and on-demand, ensuring broad accessibility for the global breast cancer community.
25 Posts Not to Miss from SABCS 2025
In this article, we selected 25 key posts you shouldn’t miss, capturing the most impactful insights, research updates, and expert perspectives shared throughout SABCS 2025.
“SABCS25: LidERA trial:
Giredestrant improved iDFS vs standard ET (HR 0.70; 3-yr iDFS 92.4% vs 89.6%).
OS trend favored giredestrant (immature).
31% reduction in distant recurrence.
Favorable safety and lower discontinuation.
My intake
– First improvement in adjuvant ET in 20 years. Potential new standard of care.
– Impressive data in high-risk patients, less so in intermediate risk but still very early.
– No CDK4/6i in LidERA. CDK4/6i has longer follow up OS in MonarchE.
– If approved, how do we combine data? How would we incorporate this data in our practice with other options available. Combination vs sequencing with CDK4/6i! ongoing trials.
– Financial implications.”
“Excited to share that our article on empowering patients on hashtag#HER2 biomarker testing in breast cancer has been published in print by Frontiers in Digital Health
This work reflects our commitment to ensuring patients have the knowledge and tools to make informed decisions about their care
The timing couldn’t be better with SABCS25 underway and the holidays approaching. Feeling so grateful for the collaboration with Outcomes4Me that made this possible
Read the full article here: https://lnkd.in/gduMrZis ”
“Day 2 of ABCS2025 did not disappoint with fantastic data in HER2CLIMB05, liDERA, and ASCENT-07!
Thrilled to watch my mentee Jasmin Hundal, M.D.,DipABLM, M.S., M.P.H from Cleveland Clinic present our work on wearables in breast cancer – so proud of her— a rising star!
Caught up with colleagues, friends, and mentees and closed out the day with my favorite event of the year: the Advancements in Oncology panel with the Oncology Brothers Rahul Gosain, MD, MBA and Rohit Gosain, MD – such a robust, honest discussion about where we’re headed.
Bonus highlight: interviewing Komal Jhaveri, MD FACP, FASCO and several other leaders in the field regarding their insights – keep an eye on OncUpdates.com for those conversations.
Energized by the data, grateful for this community, and excited to bring these advances back to our patients!”
“In a randomized trial of breast MRI imaging or not for early stage TNBC or HER2+ breast cancer, MRI had no impact on cancer recurrence or NCS rates. Yet the practice is ubiquitous in the US.”
“SABCS2025 Nick Turner presents our capi291 ctDNA data. Benefit seen in those without ESR1m and large genomic rearrangements more frequently found in ctDNA vs tissue. Nice data supporting this combination, and supports both tissue and ctDNA evals.”
“Goodbye SABCS25 it was great connecting with old friends, making new ones in the middle of practice-changing presentations for Breast Cancer! Thankful to play a part sharing our ctDNA data MD Anderson News Bora Lim in partnership with Myriad Genetics, stay tuned more to come!”
“PATINA trial: Adding palbociclib to anti-HER2 + ET prolonged PFS, and significantly reduced CNS progression (13.8% vs 20.4% at 36 mo). Otto Metzger Palbociclib may help delay or prevent CNS involvement in HR+/HER2+ mBC—important and promising findings. SABCS25”
“AI superior to tamoxifen for DFS subgroup analyses in ALTTO (BIG 2-06) by Matteo Lambertini, irrespective of age, meno status, BMI, tumor type, + treatment. Data shown make addressing sexual side effects of aromatase-inhib even more important to compliance rates sabcs25”
“Tour de force review of treatment of metastatic TNBC by Sara Tolaney of Dana-Farber’s Breast Oncology Center
. A few key points below, but highly recommend watching the entire session!”
“lidERA trial of giredestrant vs SOC ET in early ER+ BC (n=4,170; median f/u 32 mo) showed iDFS 92.4% vs 89.6% (HR 0.70), DRFI 0.69, and interim OS 0.79. Important data, though still many questions as we interpret the role of a new SERD in the adjuvant setting. Very on-point discussion by Dr. Lisa Carey.”
“TILs matter in HER2+ BC! In ShortHER trial, mapping their spatial organization with AI assessing: Immune-tumor interaction Aggregates/TLS (Hotspots) further refines prognosis beyond manual evaluation PS2-08-11 at SABCS25.”
“Maintenance palbociclib (+Pertu-Trastu in PATINA trial) can delay CNS metastases as first site of progression in HR+HER2+ metastatic breast cancer! This is such a clinically relevant result!”
“Other very important data from the PATINA trial presented at SABCS25 by the great Otto Metzger from Dana-Farber’s Breast Oncology Center showing the potential value of palbociclib in delaying or preventing CNS involvement in HER2+/HR+ advanced Breast Cancer.”
“PATINA CNS outcomes Presented by Dr. Otto MetzgerOtto Metzger from Dana-Farber’s Breast Oncology Center
-maintenance HP +/- palbociclib after THP in HR+/HER2+ MBC -palbo associated with lower cumulative risk of brain mets (13% v 19%) ! -limitation- no routine brain imaging on protocol.”
“PATINA demonstrates lower rates of CNS progression in both all pts and those with brain meta at baseline with the addition of palbociclib.”
“Day 4 of SABCS25! Come by PS05-06-02 to learn about a case of CDK-4/6i induced ILD, a very rare but severe complication in breast cancer treatment. I’m incredibly honored to be standing alongside Gayle, the patient who inspired this case report.
*posted with patient permission”
Inside SABCS 2025 with Paolo Tarantino
“Impactful SABCS25 to wrap up 2025! The pace of oncology research and clinical trials is rapidly advancing.
De-escalation trials are needed.
Incorporation of ctDNA as a biomarker is showing promise in prognosis, further work needed on clinical utility.
Exciting advancements are being made in understanding mechanisms of therapy resistance.
Multiple impactful clinical trials in HR+, HER2+, and TNBC presented.
Patient reported outcomes are exceedingly important but may not tell the whole story.
Partnering with patients should be at the center of care.”
“A jam packed SABCS25 filled with new learning, collaborations and friendship. Hope to bring back info for better care and research.
Expect more dedicated holistic efforts on menopause and breast cancer – would love to collaborate with global initiatives
Ct DNA clinical utility studies are accelerating and we will hopefully have more solid evidence to personalize care in near future
Targeted therapies and combinations are rapidly increasing and more than ever we need better predictors of both response and toxicity
Impressive engagement from many patient advocates to improve care and awarensss on the issues most important to patients”
“AI based tools were a recurring theme at SABCS25, not only for outcome prediction in early breast cancer but also for their emerging role in identifying early signals of response to specific therapies.
What stood out was that very different approaches, traditional pathology driven features versus foundation models applied to digital slides, converged on similar performance when combined with clinical data and developed as locked assays, both for prognostic assessment and treatment response signals.
For clinicians, this reframes the discussion. The question is no longer whether AI can generate meaningful predictions, but how these tools should be validated against existing assays, where they truly inform therapy selection rather than risk alone, and how to integrate them into care without increasing complexity or overtreatment.”
“So proud of the >10 posters presented by Stover Lab and collaborators at San Antonio Breast Cancer Symposium 2025!”
“In 2025, many important and long-awaited studies were published. I included them but kept the algorithms unchanged, as there are open questions about how these data will impact practice, particularly in early and metastatic HER2+ disease and mTNBC.”
“imlunestrant OS in ESR1m HR+ bcsm increased by 11.4 months, but NOT signif Benefit greater in patients with ESR1m Imlu+ abema PFS now 10.9 months Dual mutation (ESR1 and PIK3) also w/ greater benefit with addition of abema to imlunestrant 9% >G3 w/ combo”
“Imlunestrant with or without Abemaciclib in Advanced Breast Cancer (ABC): Updated Efficacy Results – (Imlunestrant + Abemaciclib vs Imlunestrant Alone) – potential new options for patients with ER + and her -2 negative patients.”
“So much fun chatting with Harold J. Burstein about our work on ESR1 and PIK3CA co-mutated landscape SABCS25.”
15 Posts Not to Miss from SABCS 2025, Part 1
20 Posts Not to Miss from SABCS 2025, Part 2
Written by Nare Hovhannisyan, MD